Renal erythropoietin-producing cells in health and disease

Tomokazu Souma, Norio Suzuki*, Masayuki Yamamoto

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

88 Scopus citations


Erythropoietin (Epo) is an indispensable erythropoietic hormone primarily produced from renal Epo-producing cells (REPs). Epo production in REPs is tightly regulated in a hypoxia-inducible manner to maintain tissue oxygen homeostasis. Insufficient Epo production by REPs causes renal anemia and anemia associated with chronic disorders. Recent studies have broadened our understanding of REPs from prototypic hypoxia-responsive cells to dynamic fibrogenic cells. In chronic kidney disease, REPs are the major source of scar-forming myofibroblasts and actively produce fibrogenic molecules, including inflammatory cytokines. Notably, myofibroblast-transformed REPs (MF-REPs) recover their original physiological properties after resolution of the disease insults, suggesting that renal anemia and fibrosis could be reversible to some extent. Therefore, understanding the plasticity of REPs will lead to the development of novel targeted therapeutics for both renal fibrosis and anemia. This review summarizes the regulatory mechanisms how hypoxia-inducible Epo gene expression is attained in health and disease conditions.

Original languageEnglish (US)
Article number167
JournalFrontiers in Physiology
Issue numberJUN
StatePublished - 2015


  • Erythropoietin
  • Fibrosis
  • Hypoxia
  • Plasticity
  • Renal Epo-producing cell (REP)

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)


Dive into the research topics of 'Renal erythropoietin-producing cells in health and disease'. Together they form a unique fingerprint.

Cite this